Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01834430 |
Recruitment Status :
Completed
First Posted : April 17, 2013
Last Update Posted : April 17, 2013
|
Sponsor:
Nanjing PLA General Hospital
Information provided by (Responsible Party):
Gao Tao, Nanjing PLA General Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Different studies suggest that early enteral nutrition (EEN) has benefits in reducing infectious complications, there is no data that addresses whether delayed enteral nutrition (EN) is detrimental and if it may have effects on inflammatory responses and immune function.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Severe Acute Pancreatitis Patients Duodenal Fistula Inflammatory Intestinal Obstruction | Dietary Supplement: enteral nutrition | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 45 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting |
Study Start Date : | February 2010 |
Actual Primary Completion Date : | February 2012 |
Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics:
Hereditary pancreatitis
Arm | Intervention/treatment |
---|---|
Experimental: EN group
The EN group gradually restored enteral nutrition, while the PN group continued to receive parenteral nutrition treatment. Both groups received between 20 to 25 kcal/kg/day and 1.5 g/kg/day of protein. Because of the low volume, concentration, and calorie amount, on the first day, tube feeding utilized 500 ml with the speed of 30 ~ 50 ml/h. On the second day, tube feeding utilized 1000 ml with the speed of 60 ~ 80 ml/h. On the third day, tube feeding utilized 1500 ~ 2000 ml with the speed of 100 ~ 120 ml/h. If enteral nutrition could not meet a patient's caloric requirements, PN supplement was started on the fourth day. The required calories and protein for each individual in the two groups was assumed to be achieved after three days of therapy. The PN group continued to receive parenteral nutrition.
|
Dietary Supplement: enteral nutrition |
No Intervention: parenteral nutrient group |
Primary Outcome Measures :
- all cause mortality [ Time Frame: 28 days ]
Secondary Outcome Measures :
- organ failure [ Time Frame: 7 days ]
Other Outcome Measures:
- inflammatory markers [ Time Frame: 7 days ]white blood cell count, C reactive protein(CRP), pro-inflammatory cytokines (TNF-a,IL-1,IL-6), and anti-inflammatory cytokines (IL-4, IL-10)
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- having a fasting time of more than 14 days
- American Society of Anesthesiologists (ASA) physical status ranging between 1 and 3, and their condition allows enteral nutrition therapy.
Exclusion Criteria:
- chronic renal failure (peritoneal or hemodialysis or creatinine > 2.5 mg/dl)
- history of chronic obstructive pulmonary disease
- hepatic dysfunction or cirrhosis or a bilirubin value > 3 mg/dl
- metabolic diseases,severe anemia
- blood coagulation dysfunction
- pregnancy lactation
- history of psychiatric illness
- patients underwent immunosuppressive therapy
No Contacts or Locations Provided
Responsible Party: | Gao Tao, Clinical Professor, Nanjing PLA General Hospital |
ClinicalTrials.gov Identifier: | NCT01834430 |
Other Study ID Numbers: |
2009NLY059 |
First Posted: | April 17, 2013 Key Record Dates |
Last Update Posted: | April 17, 2013 |
Last Verified: | April 2013 |
Additional relevant MeSH terms:
Pancreatitis Intestinal Obstruction Fistula Pathological Conditions, Anatomical |
Pancreatic Diseases Digestive System Diseases Intestinal Diseases Gastrointestinal Diseases |